Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 7, 2022

FDA grants IND clearance for REGENXBIO’s gene therapy trial for Duchenne

Set to commence in the first half of this year, the trial will initially have sites in the US.

The US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of REGENXBIO to initiate a first-in-human clinical trial of RGX-202 to treat Duchenne muscular dystrophy (Duchenne).

RGX-202 is a one-time gene therapy that leverages the NAV AAV8 vector of REGENXBIO.

It will deliver a transgene for a new microdystrophin that comprises the functional elements of the C-Terminal domain observed in naturally seen dystrophin.

The company anticipates commencing the trial in the first half of this year with study centres planned to be launched in the US in the initial stage.

Additional trial centres will subsequently be opened in Canada and Europe.

The open-label, multicentre Phase I/II dose-escalation and dose-expansion AFFINITY DUCHENNE study will assess the safety, clinical efficacy and tolerability of a single intravenous (IV) dose of RGX-202 in Duchenne patients.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The dose-escalation phase will have six ambulatory, paediatric subjects aged four to 11 years with Duchenne enrolled in two arms to receive either 1×10¹⁴ genome copies (GC)/kg body weight and 2×10¹⁴ GC/kg body weight.

Following an independent safety data analysis for each arm, a dose-expansion phase is expected to enrol up to six additional subjects in each cohort.

RGX-202’s safety, immunogenicity analysis, pharmacodynamic and pharmacokinetic measures and strength and functional evaluations are the endpoints of the trial.

REGENXBIO chief scientific officer Olivier Danos said: “Additional therapeutic options are still needed for the treatment of Duchenne, and our trial design follows compelling evidence from preclinical studies which demonstrated that one-time treatment with RGX-202 can express meaningful levels of a novel, functional microdystrophin protein in muscle, and showed significant improvements in muscle force and function in animal models.”

Duchenne is a rare genetic disease caused by mutations in the gene responsible for producing dystrophin.

Last October, the company reported initial data from the Phase II ALTITUDE trial of RGX-314 for treating diabetic retinopathy without centre-involved diabetic macular oedema.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU